Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’

Drug Safety

Volumn 42, Issue 5, 2019, Pages 689-691

  Schaffalitzky de Muckadell, Philip ^a   Strom, Claes Christian ^a  

^a Pharmacosmos AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; IRON ISOMALTOSE; FERRIC ION; IRON; MALTOSE;

ALLERGIC REACTION; ANAPHYLAXIS; CYANOSIS; DISEASE SEVERITY; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; SELECTION BIAS; SHOCK; ANALOGS AND DERIVATIVES; EUROPE;

EUROPE; FERRIC COMPOUNDS; IRON; MALTOSE;

EID: 85064283057     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-019-00814-5     Document Type: Letter

References (10)

1. Ehlken B, Nathell L, Gohlke A, Bocuk D, Toussi M, Wohlfeil S. Evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron(III) isomaltoside 1000 in Europe based on data from EudraVigilance and VigiBase™ between 2014 and 2017. Drug Saf. 2019;42(3):463-71.
2. European Medicines Agency. Rapid response to BMJ. Re: Pandemrix vaccine: why was the public not told of early warning signs? (EMA/659264/2018). 2018. https://www.ema.europa.eu/documents/other/european-medicines-agency-rapid-response-british-medical-journal-pandemrix_pdf. Accessed 18 Jan 2019.
3. Swissmedic. Vigilance-news. Edition no. 11. 2013.
4. Center for Drug Evaluation and Research. Medical review of ferric carboxymaltose (application number: 203565Orig1s000). 2013. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000MedR.pdf. Accessed 17 Jan 2019.
5. Uppsala Monitoring Centre. VigiBase. https://www.who-umc.org/vigibase/vigibase/. Accessed 1 Nov 2018.
6. Diafer 50 mg/ml solution for injection. Summary of product characteristics. 2014. Pharmacosmos UK Ltd.
7. ® (ferric carboxymaltose injection). Prescribing information. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203565s000lbl.pdf. Accessed 17 Jan 2019.
8. Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(6):529–35.
9. Wolf M. Effects of iron isomaltoside versus ferric carboxymaltose on hormonal control of phosphate homeostasis: the PHOSPHARE-IDA04/05 randomized controlled trials. In: Online abstract to the 101st annual meeting and expo of the Endocrine Society. 23–26 March 2019. New Orleans, LA. https://www.abstractsonline.com/pp8/#!/5752/presentation/16504. Accessed 1 Nov 2018.
10. Auerbach M, Thomsen LL. A single infusion of iron isomaltoside 1000 allows a more rapid hemoglobin increment than multiple doses of iron sucrose with a similar safety profile in patients with iron deficiency anemia. Blood. 2018;132:2334.